John Mendlein - Net Worth and Insider Trading
John Mendlein Net Worth
The estimated net worth of John Mendlein is at least $750,404 dollars as of 2026-08-16. John Mendlein is the Director of Fate Therapeutics Inc and owns about 282,770 shares of Fate Therapeutics Inc (FATE) stock worth over $725,305. John Mendlein is also the Director of aTyr Pharma Inc and owns about 43,956 shares of aTyr Pharma Inc (ATYR) stock worth over $25,099. Details can be seen in John Mendlein's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that John Mendlein has not made any transactions after 2023-01-13 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of John Mendlein
John Mendlein Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, John Mendlein owns 5 companies in total, including Fate Therapeutics Inc (FATE) , aTyr Pharma Inc (ATYR) , and Moderna Inc (MRNA) among others .
Click here to see the complete history of John Mendlein’s form 4 insider trades.
Insider Ownership Summary of John Mendlein
| Ticker | Company | Transaction Date | Type of Owner |
|---|---|---|---|
| FATE | Fate Therapeutics Inc | 2023-01-13 | director |
| ATYR | aTyr Pharma Inc | 2018-12-21 | director & CEO and Executive Chairman |
| MRNA | Moderna Inc | 2018-12-07 | See Remarks |
 | | 2016-02-02 | director |
| | 2021-07-29 | director |
John Mendlein Latest Holdings Summary
John Mendlein currently owns a total of 2 stocks. Among these stocks, John Mendlein owns 282,770 shares of Fate Therapeutics Inc (FATE) as of January 13, 2023, with a value of $725,305 and a weighting of 96.66%. John Mendlein also owns 43,956 shares of aTyr Pharma Inc (ATYR) as of December 21, 2018, with a value of $25,099 and a weighting of 3.34%.
Latest Holdings of John Mendlein
| Ticker | Company | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| FATE | Fate Therapeutics Inc | 2023-01-13 | 282,770 | 2.57 | 725,305 |
| ATYR | aTyr Pharma Inc | 2018-12-21 | 43,956 | 0.57 | 25,099 |
Holding Weightings of John Mendlein
John Mendlein Form 4 Trading Tracker
According to the SEC Form 4 filings, John Mendlein has made a total of 3 transactions in Fate Therapeutics Inc (FATE) over the past 5 years, including 1 buys and 2 sells. The most-recent trade in Fate Therapeutics Inc is the acquisition of 124,679 shares on January 13, 2023, which cost John Mendlein around $698,202.
According to the SEC Form 4 filings, John Mendlein has made a total of 0 transactions in aTyr Pharma Inc (ATYR) over the past 5 years. The most-recent trade in aTyr Pharma Inc is the acquisition of 17,500 shares on December 21, 2018, which cost John Mendlein around $102,900.
Insider Trading History of John Mendlein
* The information on this page (including Insider Trading Shares, Share Changes, Cost, etc.) is sourced exclusively from Form 4 filings and does not incorporate any data from 13F or 13D/G filings. As a result, it may differ from the values shown on the Guru page.
- 1
John Mendlein Trading Performance
GuruFocus tracks the stock performance after each of John Mendlein's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by John Mendlein is 16.08%. GuruFocus also compares John Mendlein's trading performance to market benchmark return within the same time period. The performance of stocks bought by John Mendlein within 3 months outperforms 6 times out of 9 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how John Mendlein's insider trading performs compared to the benchmark.
Performance of John Mendlein
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 18.09 | | | | | |
| Relative Return to S&P 500(%) | 15.49 | | | | | |
John Mendlein Ownership Network
Ownership Network List of John Mendlein
Ownership Network Relation of John Mendlein
John Mendlein Owned Company Details
What does Fate Therapeutics Inc do?
Who are the key executives at Fate Therapeutics Inc?
John Mendlein is the director of Fate Therapeutics Inc. Other key executives at Fate Therapeutics Inc include Chief Development Officer Bahram Valamehr , See Remarks Cindy Tahl , and Chief Financial Officer Kamal Adawi .
Fate Therapeutics Inc (FATE) Insider Trades Summary
Over the past 18 months, John Mendlein made no insider transaction in Fate Therapeutics Inc (FATE). Other recent insider transactions involving Fate Therapeutics Inc (FATE) include a net sale of 92,549 shares made by Bahram Valamehr , and a net sale of 84,016 shares made by Cindy Tahl .
In summary, during the past 3 months, insiders sold 137,283 shares of Fate Therapeutics Inc (FATE) in total and bought 0 shares, with a net sale of 137,283 shares. During the past 18 months, 176,565 shares of Fate Therapeutics Inc (FATE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 176,565 shares.
Fate Therapeutics Inc (FATE)'s detailed insider trading history can be found in Insider Trading Tracker table.
Fate Therapeutics Inc Insider Transactions
John Mendlein Mailing Address
Above is the net worth, insider trading, and ownership report for John Mendlein. Based on the public information released on the U.S. Securities and Exchange Commission (SEC) website, John Mendlein's mailing address is: San Diego Ca 92131.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
